Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07061938 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
A Phase 1 study of IgG4 Related Disease, sponsored by Acepodia Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT07061938 is a Phase 1 study of IgG4 Related Disease that is actively recruiting participants, run by Acepodia Biotech. The registered enrollment target is 30 participants, below the 85-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07061938, a Phase 1 study of IgG4 Related Disease, is actively recruiting participants, sponsored by Acepodia Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Conditions Studied
Interventions
- DRUG Lymphodepleting chemotherapy
- DRUG ACE1831
Study Locations (3)
Georgia
- Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
JP
- Kanazawa Medical University Hospital - Kahoku-gun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2027-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07061938
The ClinicalTrials.gov registry entry for NCT07061938 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (65% lower). The listed sponsor is Acepodia Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgG4 Related Disease appearing as the primary indexed condition, and to 2 interventions - of which Lymphodepleting chemotherapy is the first listed.
NCT07061938 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Massachusetts, JP.
Frequently Asked Questions
What is clinical trial NCT07061938 about?
NCT07061938 is a clinical study titled "Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease". ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
What is the current status of trial NCT07061938?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-01. Estimated completion is 2027-06-20.
What conditions does trial NCT07061938 study?
This clinical trial studies the following conditions: IgG4 Related Disease.
What interventions are being tested in trial NCT07061938?
The interventions under investigation include: Lymphodepleting chemotherapy (DRUG), ACE1831 (DRUG).
Who is sponsoring clinical trial NCT07061938?
This trial is sponsored by Acepodia Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07061938 being conducted?
This trial has 3 study locations across Georgia, Massachusetts, JP. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
COMPLETED · Phase 1
-
A Study of Efgartigimod in Patients With IgG4-Related Disease
RECRUITING · Phase 2
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.